Simvastatin Tablet, Film Coated
Product Images NDC 70518-4102

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Simvastatin (NDC 70518-4102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Footnote For Table 3 (Footnote For Table 3)

This text provides information about the impact of different factors on the pharmacokinetics of simvastatin. It mentions the potential CYP3A4 inhibitors that could affect simvastatin metabolism, such as Ketoconazole and erythromycin. Additionally, it discusses the use of grapefruit juice and its effect on the pharmacokinetics of simvastatin. The text describes a study where grapefruit juice was administered with simvastatin at various time points to evaluate its influence on drug levels. Overall, this information can be valuable for understanding how certain substances or medications may interact with simvastatin in the body.*

FDA Label Image

Mm1 (Simvastatin 5mg 70518 4102 00 (1))

This is a description of Simvastatin 5 mg tablets. The medication comes in a quantity of 30 tablets and is only available with a prescription. The NDC number is 70518-4102-00, and the source NDC is 70377-0001-14. The manufacturer is BieconPharma located in Iselin, NJ. The directions for use can be found in the package insert, and the medication should be stored at 20-25°C (58-77°F) with excursions permitted to 15.30°C (59-86°F). The medication has been repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Figure 9 (Simvastatin 10)

FDA Label Image

Table2 (Simvastatin 2)

This is a table showing adverse reactions reported by patients treated with Simvastatin compared to those who received a placebo. Some of the adverse reactions reported by more than 2% of patients treated with Simvastatin and greater than placebo include Edema/swelling, Abdominal pain, Atrial fibrillation, Constipation, Gastritis, Diabetes mellitus, Myalgia, Headache, Insomnia, Bronchitis, Sinusitis, Eczema, and Urinary tract infection.*

FDA Label Image

Structure (Simvastatin 3)

FDA Label Image

Table 3 (Simvastatin 4)

FDA Label Image

Table 4 (Simvastatin 5)

FDA Label Image

Figure 5 (Simvastatin 6)

FDA Label Image

Figure 6 (Simvastatin 7)

FDA Label Image

Figure 7 (Simvastatin 8)

The text provides baseline values (in mg/dL) for different parameters in a study: ToBI-G = 254, LOL-735, FDLC-36.76 = 304, VIDL-3, and non-AL-75. These values likely represent medical data for patients in the study.*

FDA Label Image

Figure 8 (Simvastatin 9)

FDA Label Image

Table 1 (Table1)

This is a list of drug interactions associated with an increased risk of myopathy or rhabdomyolysis. It includes interactions with strong CYP3A4 inhibitors, HIV protease inhibitors, certain products like gemfibrozil and cyclosporine, as well as specific recommendations for drugs such as niacin, verapamil, diltiazem, and amiodarone. It also provides advice for patients with HOFH (homozygous familial hypercholesterolemia) and mentions precautions like temporarily suspending simvastatin with daptomycin and avoiding grapefruit juice.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.